A survey of heparin monitoring in Australasia

Pathology

Volumn 28, Issue 4, 1996, Pages 343-347

  Mackinlay, Naomi ^a   Favaloro, Emmanuel ^b   Arthur, Chris ^a   Smith, Julian ^b   Aboud, Margaret ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

APTT; Heparin monitoring

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ARTICLE; AUSTRALIA; CLINICAL PRACTICE; DRUG MONITORING; HEPARINIZATION; LABORATORY TEST; METHODOLOGY; PARTIAL THROMBOPLASTIN TIME; STANDARDIZATION; THROMBOEMBOLISM;

EID: 0030440405     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313029600169314     Document Type: Article

References (17)

1. Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time - A difference between in-vitro and in-vivo effects and the implications for the therapeutic range. Am J Clin Pathol 1980; 74: 668-73.
2. Brill-Edwards P, Ginsberg J, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Int Med 1993; 119: 104-9.
3. Favaloro E, Grispo L. Comparative evaluation of 17 Commercial APTT reagents. Aust J Med Sci 1994; 15: 133-40.
4. Hirsh J. Anticoagulant therapy in venous thromboembolism. Balliere's Clin Hematol 1990; 3: 685-92.
5. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulent and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-84.
6. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin therapy with the APTT. N Engl J Med 1972; 287: 324-7.
7. Hull R, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109-14.
8. Hull R, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-4.
9. Turpie AG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ et al. Comparison of high dose with low dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural myocardial infarction. N Engl J Med 1989; 320: 352-7.
10. Brandt JT, Triplett DA. Laboratory Monitoring of heparin. Effect of reaeents and instruments on the activated partial thromboplastin time. Am J Clin Pathol 1981; 76: 530-7.
11. Zanke B, Shojania AM. Comparison of two APTT methods of monitoring heparin therapy. Am J Clin Pathol 1990; 93: 684-9.
12. van den Bessalaar AMJH, Meeuuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex vivo heparin samples. Thromb Hemost 1990; 63: 16-23.
13. Scialla SJ. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardisation. Am J Clin Pathol 1985; 84: 351-4.
14. Gallus AS, Hirsh J, Gent M. Relevance of preoperative and postoperative blood tests in postoperative leg vein thrombosis. Lancet 1973; ii: 805-9.
15. College of American Pathologists. Comprehensive Coagulation Survey, 1995 Set GC2-A. Participant Summary.
16. Reed SV, Haddon ME, Denson KW. An attempt to standarise the APTT for heparin monitoring, using the P.T. ISI/INR system of calibration. Results of a 13 centre study. Thromb Res 1994; 74: 515-22.
17. Van der Velde EA, Poller L. The APTT monitoring of heparin - The ISTH/ICSH Collaborative Study. Thromb Hemost. 1995; 73: 73-81.